Neurophyxia

Executive Summary

Neurophyxia is a clinical-stage biopharmaceutical company based in Leiden, Netherlands, dedicated to developing novel neuroprotective therapies for brain damage resulting from oxygen deprivation. Its lead small-molecule candidate, 2-iminobiotin (2-IB), is designed to mitigate neuronal injury in conditions such as stroke, cardiac arrest, and birth asphyxia. Currently in Phase 1 clinical development, 2-IB has shown promise in preclinical models by targeting key pathways involved in oxidative stress and inflammation. The company's focus on acute neurological indications addresses significant unmet medical needs, with limited treatment options currently available for these life-threatening events. Neurophyxia's approach leverages a strong foundation of academic and industry expertise, positioning it to advance 2-IB through early-stage clinical trials and potentially establish a new standard of care for neuroprotection.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 data readout for 2-IB in stroke/cardiac arrest50% success
• 2027Initiation of Phase 2 trial for birth asphyxia70% success